FibroBiologics begins phase 1/2 trial for diabetic foot ulcer therapy

June 3, 2026 7:00 AM

FibroBiologics Inc. (NASDAQ: FBLG) announced that it has dosed the first patients in a Phase 1/2 clinical trial evaluating CYWC628 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found